Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 366
- Registration Number
- NCT04471428
- Locations
- 🇺🇸
Kaiser Permanente - San Diego, San Diego, California, United States
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇦🇹Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT04467723
- Locations
- 🇺🇸
The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
- Conditions
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-02-23
- Target Recruit Count
- 104
- Registration Number
- NCT04462276
- Locations
- 🇩🇪
Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany
🇦🇹Kepler Universitätsklinikum, MC III., Pneumologie, Linz, Austria
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT04458922
- Locations
- 🇺🇸
Siteman Cancer Center-South County, Saint Louis, Missouri, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04449874
- Locations
- 🇺🇸
UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 575
- Registration Number
- NCT04446117
- Locations
- 🇺🇸
Exelixis Clinical Site #6, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #18, Philadelphia, Pennsylvania, United States
🇵🇱Exelixis Clinical Site #243, Otwock, Mazowieckie, Poland
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Kahr Medical
- Target Recruit Count
- 125
- Registration Number
- NCT04440735
- Locations
- 🇺🇸
Moores Cancer Center, UCSD, La Jolla, California, United States
🇺🇸University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04434040
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Chicago Medical Center for Advanced Care Orland Park, Orland Park, Illinois, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 24
- Registration Number
- NCT04432207
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04426825
- Locations
- 🇨🇳
Sun Yet-sen University Cancer Center, Guangzhou City, China
🇨🇳Beijing Hospital; Internal Medicine-Oncology, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.